Why Black men's prostate cancer may be more responsive to immunotherapy

February 10, 2021

CHICAGO--- Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from immunotherapy treatment. A new Northwestern Medicine study discovered the reason appears to be an increase of a surprising type of immune cell in the tumor. The findings could lead to immune-based precision medicine treatment for men of all races with localized aggressive and advanced prostate cancer.

In the new study, Northwestern scientists showed tumors from Black men and men of African ancestry have an increased proportion of a special immune cell called plasma cells compared to the tumors of white men. A research team lead by Dr. Edward Schaeffer, chair of urology at Northwestern University Feinberg School of Medicine and Northwestern Medicine, found this increase in plasma cells correlated with improved cancer survival following surgery and identify plasma cells as potential drivers of prostate cancer immune-responsiveness.

The study will be published on Feb. 10 in Nature Communications.

"If a man's prostate cancer has numerous plasma cells, we found he had improved cancer survival," Schaeffer said. "Our study suggests plasma cells are important in the body's response to cancer."

Although recent research suggests Black men with advanced prostate cancer have improved survival outcomes with immunotherapy, there has been no way to predict which individual patients -- Black or white -- with prostate cancer may respond best to immunotherapy drugs.

Schaeffer's team explored this by analyzing the genomics of 1,300 tumor samples annotated with self-identified race or genetic ancestry. They found, on average, more plasma cells in Black men's tumors than white men's.

The finding was not unique to Black men, and the work showed that in all men with elevated plasma cell levels there was improved cancer-free survival following surgery.

"The finding comes at a time as researchers are discovering plasma cells may play a greater role in cancer immunotherapy than previously thought," said first author Dr. Adam Weiner, a Northwestern Medicine urology resident. "Testing for plasma cells in prostate cancer may help identify men who will benefit from immune-based treatments."

Schaeffer's research team at the Polsky Urologic Cancer Institute at the Robert H. Lurie Comprehensive Center of Northwestern University is now developing immunotherapy-based precision medicine clinical trials to investigate whether increased levels of plasma cells in prostate cancers from men of all races and ancestry can enhance the efficacy of immunotherapy and improved survival.

Prostate cancer is the second most common cancer in American men with an estimated 175,000 new cases every year and about 32,000 deaths. The severity and resulting mortality from prostate cancer are about two times greater in patients of African American origin.

Identification and characterization of effective therapeutic targets is a significant and unmet need to improve clinical outcomes and reduce mortality from lethal prostate cancer among African American men.
-end-
The research was supported by the Polsky Urologic Cancer Institute, grant 5U01CA196390 from National Cancer Institute of the National Institutes of Health, the Prostate Cancer Foundation, the 2019 Urology Care Foundation Residency Research Award Program and the Russell Scott, Jr., MD Urology Research Fund.

Northwestern University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.